Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate the use of amlodipine, a drug that blocks the uptake of
calcium into cells, in the prevention and treatment of iron overload in patients with
thalassemia major. Since iron uses the same calcium channels to enter the heart, pancreas and
other organs, blocking these channels might help to prevent the accumulation of iron in these
tissues. The study will follow 60 patients with thalassemia major: 30 will receive amlodipine
and 30 will serve as controls receiving placebo in a randomized double-blind fashion.
Patients will be monitored through one year. Monitoring will occur through the measurement of
blood ferritin as well as live and heart T2* by MRI initially, at 6 and 12 months.
Phase:
Phase 3
Details
Lead Sponsor:
University of Campinas, Brazil
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo